Evidence map›Paper›PMID 40189958›Full record

ArticleBrachytherapy

Primary vaginal cancer treated with high-dose rate brachytherapy and intraprocedural magnetic resonance imaging.

Ulysses G Gardner, Keara English, Michael Roumeliotis, Serena Mao, Todd McNutt, Mohammad Rezaee, Junghoon Lee, Akila N Viswanathan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brachytherapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ulysses G GardnerDepartment of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD.
Keara EnglishDepartment of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD.
Michael RoumeliotisDepartment of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD.
Serena MaoDepartment of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD.
Todd McNuttDepartment of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD.
Mohammad RezaeeDepartment of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD.
Junghoon LeeDepartment of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD.
Akila N ViswanathanDepartment of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: anv@jhu.edu.

Funding

Multiparametric Magnetic Resonance Imaging as a Novel Approach to Brachytherapy for Cervical CancerR01CA237005 · NCI · JOHNS HOPKINS UNIVERSITY · PI VISWANATHAN, AKILA · 2020 to 2024
$2.8M
NCI NIH HHS R01 CA237005
6 · The paper itself

Abstract

purposeTo report outcomes among primary vaginal cancer patients treated definitively with either external beam radiation therapy plus high-dose rate (HDR) brachytherapy (EBRT-BT) or BT (BT) alone with placement of interstitial catheters under magnetic resonance imaging (MRI) guidance.

methodsRetrospective review of 41 patients treated for primary vaginal cancer from 2016 to 2022. Kaplan-Meier (KM) estimates were generated for disease-free survival (DFS), local control (LC), and overall survival (OS).

resultsMedian follow-up was 28 months (range 2-82 months). A total of 36 patients had EBRT-BT, 5 had BT alone. Forty patients had template interstitial and 1 had a multichannel cylinder. Among patients who received EBRT-BT, median total D90 EQD2 was 68.3 Gray (Gy) (range 56.6-91.5 Gy); BT only, median 40.3 Gy (range 38.1-86.3 Gy). No patient experienced local only failure. Relapse occurred in 12 patients treated with EBRT-BT versus 1 with BT alone group. For the EBRT-BT cohort versus BT only cohort, 2-year OS was 81% versus 60%, DFS 61% versus 40%, and LC was 94% versus 80%, respectively. For the entire cohort, 2-year OS was 67%, and median OS was 5 years. The 2-year DFS was 57% and 2-year LC was 93%. The most common any grade acute treatment-related toxicity were grade 1 vaginal pain and stenosis. Grade 3 acute and late toxicities were minimal.

conclusionsMRI-guided HDR BT for primary vaginal cancer yields high rates of local control with limited toxicities. Lower rates of distant control indicate the need for newer options such as immunotherapy or other systemic agents.

Indexed as

BrachytherapyMagnetic Resonance ImagingVaginal NeoplasmsAdultAgedAged, 80 and overFemaleHumansMiddle AgedRadiotherapy DosageRetrospective StudiesTreatment OutcomeMRI-guided brachytherapyVaginal cancer

Identifiers

PMID40189958
PMCPMC12226236

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.